title: Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2cm or larger: A literature review and analysis of oncological and obstetrical outcomes.
abstract: Radical trachelectomy is the treatment of choice in women with early-stage cervical cancer wishing to preserve fertility. Radical trachelectomy can be performed with a vaginal, abdominal, or laparoscopic/robotic approach. Vaginal radical trachelectomy (VRT) is generally not offered to patients with tumors 2cm or larger because of a high recurrence rate. There are no conclusive recommendations regarding the safety of abdominal radical trachelectomy (ART) or laparoscopic radical trachelectomy (LRT) in such patients. Several investigators have used neoadjuvant chemotherapy in patients with tumors 2 to 4cm to reduce tumor size so that fertility preservation may be offered. However, to our knowledge, no published study has compared outcomes between patients with cervical tumors 2cm or larger who underwent immediate radical trachelectomy and those who underwent neoadjuvant chemotherapy followed by radical trachelectomy. We conducted a literature review to compare outcomes with these 2 approaches. Our main endpoints for evaluation were oncological and obstetrical outcomes. The fertility preservation rate was 82.7%, 85.1%, 89%; and 91.1% for ART (tumors larger than >2cm), ART (all sizes), NACT followed by surgery and VRT (all sizes); respectively. The global pregnancy rate was 16.2%, 24% and 30.7% for ART, VRT, and NACT followed by surgery; respectively. The recurrence rate was 3.8%, 4.2%, 6%, 7.6% and 17% for ART (all sizes), VRT (all sizes), ART (tumors>2cm), NACT followed by surgery, and VRT (tumors>2cm). These outcomes must be considered when offering a fertility sparing technique to patients with a tumor larger than 2cm.
authors.affiliation: Department of Gynecologic Oncology, Instituto de Cancerología Las Américas, Medellín, Colombia.
authors.forename: Rene
authors.initials: R
authors.lastname: Pareja
authors.affiliation: Department of Gynecologic Oncology, Instituto de Cancerología Las Américas, Medellín, Colombia.
authors.forename: Gabriel J
authors.initials: GJ
authors.lastname: Rendón
authors.affiliation: Department of Gynecologic Oncology, Hospital Universitario San Vicente de Paul, Medellín, Colombia.
authors.forename: Monica
authors.initials: M
authors.lastname: Vasquez
authors.affiliation: Department of Gynecologic Oncology, Instituto de Cancerología Las Américas, Medellín, Colombia; Gynecologic Oncology Unit, Hospital San José, Bogotá, Colombia.
authors.forename: Lina
authors.initials: L
authors.lastname: Echeverri
authors.affiliation: Head Gynecologic Oncology Unit, Group of Hospitals, Madrid, Spain.
authors.forename: Carlos Millán
authors.initials: CM
authors.lastname: Sanz-Lomana
authors.affiliation: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: peramire@mdanderson.org.
authors.forename: Pedro T
authors.initials: PT
authors.lastname: Ramirez
mesh_terms: D017024:Chemotherapy, Adjuvant; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000379:methods; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*
keywords: Cervical cancer; Conservative; Neoadjuvant